2021/05/10 ALA-1000 Receive notice of patent allowance from Innovation, Science and Economic Development Canada (ISED), Application No.3,033,046 Post author:alarpharm Post published:8 . 6 . 2021 Post category:Media releases You Might Also Like 2021/04/13 -Alar Pharmaceuticals Inc., participates in American Society of Addiction Medicine (ASAM) Virtual 2021, the nation’s largest and premier conference on addiction medicine, which will hold this year between 22 – 24 April. 13 . 4 . 2021 2021/08/25 ALA-1000 Receive notice of patent allowance from South Africa-Companies and Intellectual Property Commission Department of Trade and Industry (CIPC), Application No. 2019/00890. 3 . 9 . 2021 2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. 3 . 5 . 2021 2020/08/21 Alar Pharmaceuticals Inc. Completes Pre-IND Meeting with US FDA for ALA-3000 24 . 8 . 2020 2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients 10 . 3 . 2021
2021/04/13 -Alar Pharmaceuticals Inc., participates in American Society of Addiction Medicine (ASAM) Virtual 2021, the nation’s largest and premier conference on addiction medicine, which will hold this year between 22 – 24 April. 13 . 4 . 2021
2021/08/25 ALA-1000 Receive notice of patent allowance from South Africa-Companies and Intellectual Property Commission Department of Trade and Industry (CIPC), Application No. 2019/00890. 3 . 9 . 2021
2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. 3 . 5 . 2021
2020/08/21 Alar Pharmaceuticals Inc. Completes Pre-IND Meeting with US FDA for ALA-3000 24 . 8 . 2020
2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients 10 . 3 . 2021
